(Bloomberg) — The Food and Drug Administration’s rejection of a pair of medicines that Wall Street expected to sail by regulators raised concerns that other upcoming drug decisions could meet a similar fate.Setbacks for Galapagos NV and Gilead Sciences Inc.’s rheumatoid arthritis treatment and BioMarin Pharmaceutical Inc.’s hemophilia A gene therapy turned up the heat for biotechnology investors betting on companies with key decisions in the coming months. Shares fell as Biogen Inc.’s experimental Alzheimer’s disease drug and Bristol Myers Squibb Co.’s medicines acquired from Celgene Corp. were seen among those at risk.“I’m getting the question a lot about how …read more
Source:: Yahoo Finance
